Muntz H G, Tarraza H M, Goff B A, Granai G O, Rice L W, Nikrui N, Fuller A F
Department of Gynecology, Massachusetts General Hospital, Boston 02114.
Gynecol Oncol. 1991 Mar;40(3):268-73. doi: 10.1016/0090-8258(90)90290-2.
Advanced adenocarcinoma of the fallopian tube has a poor prognosis, with 5-year survival rates commonly less than 20%. Since 1980, we have managed 12 patients with disseminated tumor with combination chemotherapy following surgical cytoreduction. Analogous to the International Federation of Gynecology and Obstetrics staging of ovarian carcinoma, 3 patients were classified in Stage II, 8 in Stage III, and 1 in Stage IV. Ten patients received cisplatin-containing regimens. The 3 Stage II patients, without measurable disease after primary surgery, had an indeterminate response to chemotherapy. In Stages III-IV there were 4 complete responses (3 confirmed by second-look laparotomy) and 2 partial responses, for an overall response rate of 67%. Disease progressed in 2 patients and was stable in 1 patient. After median follow-up of 3.5 years, 4 of the Stage III-IV patients have no evidence of disease, 1 is alive with disease, and 4 are dead.
晚期输卵管腺癌预后较差，5年生存率通常低于20%。自1980年以来，我们对12例手术细胞减灭术后出现播散性肿瘤的患者采用联合化疗进行治疗。类似于国际妇产科联盟（FIGO）的卵巢癌分期，3例患者为Ⅱ期，8例为Ⅲ期，1例为Ⅳ期。10例患者接受了含顺铂的化疗方案。3例Ⅱ期患者在初次手术后无可测量病灶，化疗反应不确定。在Ⅲ - Ⅳ期患者中，有4例完全缓解（3例经二次剖腹探查证实），2例部分缓解，总缓解率为67%。2例患者疾病进展，1例病情稳定。中位随访3.5年后，Ⅲ - Ⅳ期患者中有4例无疾病证据，1例带瘤生存，4例死亡。
